Moderna says it is in the process of developing a single-shot vaccine that could serve as a COVID-19 booster shot and a flu shot.
In a press release Thursday touting its fifth annual “R&D Day,” Moderna said it had several new mRNA vaccines in development, including one that combines a flu shot and a COVID-19 vaccine booster.
The company didn’t say when the Phase 1 trials would begin or how far the shot is in development.
“I am proud of the progress that the Moderna team has made in advancing our best-in-class mRNA pipeline while addressing the global COVID-19 pandemic,” Moderna CEO Stéphane Bancel said. We believe that our mRNA platform will solve some of the most pressing health problems in the world, including diseases that affect millions and rare diseases that impact dozens. It can also allow for personalized medicine down to the individual level.
This announcement comes as Moderna’s COVID-19 booster shots are being considered by the FDA. In August, the White House advised that all Americans fully vaccinated start seeking out a booster beginning Sept. 20. However, reports indicate that the FDA’s approval of Moderna’s booster shot might not come until early October.
Moderna also announced that four vaccine candidates were developed by the company to be used as boosters against the current variants of concern. This includes the delta variant.